PMID- 36703925
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230202
IS  - 1664-042X (Print)
IS  - 1664-042X (Electronic)
IS  - 1664-042X (Linking)
VI  - 13
DP  - 2022
TI  - The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A 
      systematic review and meta-analysis.
PG  - 1081920
LID - 10.3389/fphys.2022.1081920 [doi]
LID - 1081920
AB  - Objective: The study aimed to evaluate the effect of sodium-glucose transporter 2 
      (SGLT-2) inhibitors on various parameters of exercise capacity and provide an 
      evidence-based basis for type 2 diabetes mellitus (T2DM) combined with heart 
      failure (HF) patients or HF patients without T2DM who use SGLT-2 inhibitors to 
      improve cardiorespiratory fitness (CRF). Methods: According to the participant, 
      intervention, comparison, and outcome (PICO) elements, the effects of SGLT-2 
      inhibitor administration on VO(2) or VO(2)peak were researched in this study. 
      Weighted mean difference (WMD) and 95% confidence intervals (CIs) were calculated 
      (random-effects model). Heterogeneity was assessed by the I(2) test. Results: Six 
      studies were included according to the eligibility criteria: four were RCTs, and 
      two were non-RCTs. Compared with the control group, the merge results of RCTs 
      showed that SGLT-2 inhibitors could significantly increase the VO(2)peak (WMD, 
      2.02 ml kg(-1) min(-1), 95% CI: 0.68-3.37, and p = 0.03; I(2) = 0% and p = 0.40) 
      and VAT (WMD, 1.57 ml kg(-1) min(-1), 95% CI: 0.06-3.07, and p = 0.04; I(2) = 0% 
      and p = 0.52) of the obese population, patients with T2DM, and chronic HF 
      patients with or without T2DM. Subgroup analysis showed that SGLT-2 inhibitors 
      improved the VO(2)peak in non-HF patients (WMD, 3.57 ml kg(-1) min(-1), 95% CI: 
      0.87-6.26, and p = 0.009; I(2) = 4% and p = 0.31) more than in HF patients (WMD, 
      1.46 ml kg(-1) min(-1), 95% CI: -0.13-3.04, and p = 0.07; I(2) = 0% and p = 
      0.81). Moreover, the merge of single-arm studies also indicated that 
      empagliflozin could improve VO(2)peak (MD, 1.11 ml kg(-1) min(-1), 95% CI: 
      0.93-1.30, and p = 0.827, Delta p = 0.000 and I(2) = 0%) of T2DM patients with 
      chronic HF. Conclusion: Despite the limited number of studies and samples 
      involved, the meta-analysis preliminarily demonstrated that SGLT-2 inhibitors 
      could improve some parameters of exercise capacity (VO(2)peak, VAT) in chronic HF 
      patients with or without T2DM and obese individuals, which had a positive effect 
      on promoting cardiopulmonary fitness to help these populations improve their 
      prognosis. Systematic Review Registration: 
      [https://www.crd.york.ac.uk/prospero/#recordDetails], identifier 
      [CRD42020202788].
CI  - Copyright (c) 2023 Peng, Qin, Wang, Xue, Qin and Xu.
FAU - Peng, Yong
AU  - Peng Y
AD  - School of Kinesiology, Shanghai University of Sport, Shanghai, China.
AD  - Jiangsu Collaborative Innovation Center for Sports and Health Project, Nanjing 
      Sport Institute, Nanjing, Jiangsu, China.
AD  - Key Laboratory of Human Sports Science for Jiangsu Province, Nanjing Sport 
      Institute, Nanjing, Jiangsu, China.
FAU - Qin, Di
AU  - Qin D
AD  - School of Sport Health, Nanjing Sport Institute, Nanjing, Jiangsu, China.
FAU - Wang, Yudi
AU  - Wang Y
AD  - School of Physical Education and Nursing, Chengdu College of Arts and Sciences, 
      Chengdu, China.
FAU - Xue, Lian
AU  - Xue L
AD  - Key Laboratory of Human Sports Science for Jiangsu Province, Nanjing Sport 
      Institute, Nanjing, Jiangsu, China.
FAU - Qin, YaXuan
AU  - Qin Y
AD  - School of Sport Health, Nanjing Sport Institute, Nanjing, Jiangsu, China.
FAU - Xu, Xin
AU  - Xu X
AD  - School of Kinesiology, Shanghai University of Sport, Shanghai, China.
LA  - eng
PT  - Systematic Review
DEP - 20230110
PL  - Switzerland
TA  - Front Physiol
JT  - Frontiers in physiology
JID - 101549006
PMC - PMC9871354
OTO - NOTNLM
OT  - SGLT-2 inhibitors
OT  - T2DM
OT  - VO2peak
OT  - exercise capacity
OT  - heart failure
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/01/28 06:00
MHDA- 2023/01/28 06:01
PMCR- 2023/01/10
CRDT- 2023/01/27 02:17
PHST- 2022/10/27 00:00 [received]
PHST- 2022/12/12 00:00 [accepted]
PHST- 2023/01/27 02:17 [entrez]
PHST- 2023/01/28 06:00 [pubmed]
PHST- 2023/01/28 06:01 [medline]
PHST- 2023/01/10 00:00 [pmc-release]
AID - 1081920 [pii]
AID - 10.3389/fphys.2022.1081920 [doi]
PST - epublish
SO  - Front Physiol. 2023 Jan 10;13:1081920. doi: 10.3389/fphys.2022.1081920. 
      eCollection 2022.